Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 28;29(2):578-588.
doi: 10.3390/curroncol29020052.

Clinical Outcomes and Prognosis Analysis of Younger Bladder Cancer Patients

Mierxiati Abudurexiti  1   2   3 , Jie Ma  1   2 , Yao Li  1   2 , Chuanyi Hu  1   2 , Zhikang Cai  1   2 , Zhong Wang  1   2   4 , Ning Jiang  1   2
Affiliations

Clinical Outcomes and Prognosis Analysis of Younger Bladder Cancer Patients

Mierxiati Abudurexiti et al. Curr Oncol. .

Abstract

Background: Generally, little is known about prognostic factors in bladder cancer patients under 40 years of age. We therefore performed a retrospective study to identify prognostic factors in these younger bladder cancer patients.

Methods: We collected clinicopathological data on bladder cancer patients ≤40 years old diagnosed between 1975 and 2018 from the Surveillance, Epidemiology, and End Results (SEER) database. Survival curves were generated using the Kaplan-Meier method, and the differences between groups were analyzed using the log-rank test. Univariate and multivariate Cox hazards regression analyses were performed to define hazard ratios (HRs) for cancer-specific survival (CSS).

Results: There were statistical differences in race, histological type, cancer stage, tumor size, and surgery treatment groups between overall survival and CSS. Only tumor size and cancer stage were significant independent prognostic risk factors in younger bladder cancer patients for the prediction of CSS.

Conclusion: Tumors greater than 30 mm in size and a more advanced stage of bladder cancer were indicative of a poor prognosis in bladder cancer patients ≤40 years old, and long-term follow-up is suggested.

Keywords: 40 years; bladder cancer; prognostic factors; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart showing selection and analysis process. AJCC = American Joint Committee on Cancer.
Figure 2
Figure 2
Survival analysis in younger bladder cancer patients at the age of diagnosis (A) OS, (B) CSS, and year of diagnosis (C) OS, (D) CSS. OS = overall survival; CSS = cancer-specific survival.
Figure 3
Figure 3
Survival analysis in younger bladder cancer patients with gender (A) OS, (B) CSS, race (C) OS, (D): CSS, and histological type (E) OS, (F) CSS. OS = overall survival; CSS = cancer-specific survival.
Figure 4
Figure 4
Survival analysis in younger bladder cancer patients with AJCC cancer stage based on each edition of the AJCC Manual (A,B) AJCC Manual 3rd edition; (C,D) AJCC Manual 6th edition; (E,F) AJCC Manual 7th edition) and node-positive rate (positive/examined) (G,H). Left column: overall survival; right column: cancer-specific survival.
Figure 5
Figure 5
Survival analysis in younger bladder cancer patients with tumor size, treatment strategy, and household median income (A,C,E) overall survival; (B,D,F) cancer-specific survival.
See this image and copyright information in PMC

References

    1. Cancer Today. [(accessed on 25 September 2021)]. Available online: https://gco.iarc.fr/today/online-analysis-tble?v=2020&mode=cancer&mode_p....
    1. Rouprêt M., Babjuk M., Burger M., Capoun O., Cohen D., Compérat E.M., Cowan N.C., Dominguez-Escrig J.L., Gontero P., Mostafid A.H., et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. Eur. Urol. 2020;79:62–79. doi: 10.1016/j.eururo.2020.05.042. - DOI - PubMed
    1. He H., Liu T., Han D., Li C., Xu F., Lyu J., Gao Y. Incidence Trends and Survival Prediction of Urothelial Cancer of the Bladder: A Population-Based Study. World J. Surg. Oncol. 2021;19:221. doi: 10.1186/s12957-021-02327-x. - DOI - PMC - PubMed
    1. Abudurexiti M., Xie H., Jia Z., Zhu Y., Zhu Y., Shi G., Zhang H., Dai B., Wan F., Shen Y., et al. Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer. Front. Oncol. 2019;9:856. doi: 10.3389/fonc.2019.00856. - DOI - PMC - PubMed
    1. Compérat E., Larré S., Roupret M., Neuzillet Y., Pignot G., Quintens H., Houéde N., Roy C., Durand X., Varinot J., et al. Clinicopathological Characteristics of Urothelial Bladder Cancer in Patients Less Than 40 Years Old. Virchows Arch. 2015;466:589–594. doi: 10.1007/s00428-015-1739-2. - DOI - PubMed